Cassava Sciences, Inc. (SAVA)

In January 2026, Phase 3 results for Simufilam in Alzheimer's disease were published but did not meet pre-specified endpoints, although the safety profile was confirmed. In December 2025, Cassava Sciences settled securities class action litigation for $31.25 million. In November 2025, the company reported Q3 2025 financial results and noted Simufilam's advancement towards a clinical study for TSC-related epilepsy in the first half of 2026. In October 2025, Dawn C. Bir was appointed to the Board of Directors. In August 2025, Cassava Sciences participated in the H.C. Wainwright conference, reported Q2 2025 financial results, appointed Dr. Joseph Hulihan as Chief Medical Officer, and reported positive preclinical study results for Simufilam in TSC-related epilepsy. In June 2025, the company presented preclinical Simufilam data at a TSC Alliance Meeting. In May 2025, Cassava Sciences reported its Q1 2025 financial results. In November 2024, the stock crashed 84% after Phase 3 trials for Simufilam in Alzheimer's disease failed, leading to the halt of further studies for this indication. In October 2024, the SEC levied a $40 million fine against Cassava Sciences for allegedly concealing the failure of its Phase 2b clinical trials. In June 2024, a science advisor to the company was indicted for defrauding the National Institutes of Health.

There is no specific information available to indicate demand seasonality for Cassava Sciences' products and services. While studies have observed seasonal fluctuations in certain lab tests among Alzheimer's disease patients, this relates to diagnostic markers and not directly to the demand for the company's specific drug or diagnostic products. The overall market for Alzheimer's disease diagnostics and treatment is projected to grow, driven by increasing dementia cases, but this growth is not described as seasonal. Similarly, information regarding TSC-related epilepsy treatments focuses on prevalence and treatment strategies, without mentioning demand seasonality for related products.

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, specializing in developing treatments for central nervous system disorders, particularly Alzheimer's disease and TSC-related epilepsy. Their lead product candidate is Simufilam, a small molecule drug, and they also have an investigational diagnostic product candidate called SavaDx. The company receives support from the National Institutes of Health (NIH).

Cassava Sciences' primary activities are concentrated in North America and Australia. The company aims to establish partnerships and expand its research footprint globally as its therapeutic and diagnostic programs advance towards regulatory approval.

Cassava Sciences' brand reputation has been significantly impacted by the failure of Phase 3 clinical trials for Simufilam, an SEC fine for allegedly hiding previous trial failures, and the indictment of a science advisor for defrauding the NIH. Analyst ratings reflect this, with a consensus rating of "Reduce" and some analysts issuing "Strong Sell" recommendations.

Cassava Sciences, Inc. has 136 institutional owners and shareholders holding a total of 14,255,258 shares. Major institutional shareholders include Vanguard Group Inc, Marshall Wace, Llp, BlackRock, Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Two Sigma Advisers, Lp, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Jpmorgan Chase & Co, Two Sigma Investments, Lp, Geode Capital Management, Llc, and Group One Trading, L.p. Individual insiders also hold a significant portion of the company's stock, with Eastbourne Capital Management LLC (29.25%) and Remi Barbier (18.27%) being among the largest individual shareholders.